Review Article
Liquid biopsy and biomarkers in pancreatic ductal adenocarcinoma: from concept to clinical translation—a narrative review
Annals of Pancreatic Cancer
2026;
9:
16
.
(30 May 2026)
Editorial Commentary
Can preoperative radiotherapy reduce the risk of postoperative pancreatic fistula after pancreatoduodenectomy?
Annals of Pancreatic Cancer
2026;
9:
15
.
(30 May 2026)
Editorial Commentary
Comparing neoadjuvant regimens in resectable and borderline resectable pancreatic cancer: lessons from PREOPANC-2
Annals of Pancreatic Cancer
2026;
9:
14
.
(30 May 2026)
Editorial Commentary
CDK4/6 inhibition in pancreatic cancer: lessons learned as the therapeutic landscape evolves
Annals of Pancreatic Cancer
2026;
9:
13
.
(30 May 2026)
Editorial Commentary
Cluster of differentiation 40 agonism as a priming strategy in pancreatic ductal adenocarcinoma: biomarker insights from OPTIMIZE-1
Annals of Pancreatic Cancer
2026;
9:
12
.
(30 May 2026)
Editorial Commentary
PASS-01: the final step on the journey towards the optimal chemotherapy regimen for metastatic pancreatic adenocarcinoma?
Annals of Pancreatic Cancer
2026;
9:
11
.
(30 May 2026)
Editorial Commentary
Perioperative therapy to control hepatic micrometastases in pancreatic ductal adenocarcinoma: an appraisal of the TOSPAC-02 study
Annals of Pancreatic Cancer
2026;
9:
10
.
(30 May 2026)
Editorial Commentary
The evolving neoadjuvant landscape in pancreatic cancer: biology often overrides anatomy in achieving margin-negative resection
Annals of Pancreatic Cancer
2026;
9:
9
.
(30 May 2026)
Editorial Commentary
Stereotactic body radiotherapy in pancreatic ductal adenocarcinoma: interpreting the results of the SPAN-C trial
Annals of Pancreatic Cancer
2026;
9:
8
.
(30 May 2026)